Robin Cornelissen, MD, PhD, on ZENITH20-4: Use of Poziotinib Under Study in HER2 Exon 20–Mutated NSCLC

Posted: Tuesday, September 28, 2021

Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, talks about how new data on poziotinib, a novel tyrosine kinase inhibitor, may alter the treatment landscape for newly diagnosed patients with HER2 exon 20–mutated non–small cell lung cancer. The mutation is found in up to 4% of patients with NSCLC.